CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES

Increased incidence of allergic diseases worldwide reflects some mangles of the existing pharmacotherapy concept which ignores some etiopathogenetic aspects of clinical atopy. Meanwhile, understanding cellular and molecular mechanisms of allergy may create prerequisites for development of new therap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	N. V. Kolesnikova, I. G. Kozlov, S. V. Guryanova, E. A. Kokov, T. M. Andronova
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2016
Materias:	glucosaminyl muramyl dipeptide (gmdp) allergic diseases atopy pathogenesis ige Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/57fb33f05cbf4155ba78d2433241ed42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57fb33f05cbf4155ba78d2433241ed42
record_format	dspace
spelling	oai:doaj.org-article:57fb33f05cbf4155ba78d2433241ed422021-11-18T08:03:45ZCLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES1563-06252313-741X10.15789/1563-0625-2016-1-15-20https://doaj.org/article/57fb33f05cbf4155ba78d2433241ed422016-04-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/984https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XIncreased incidence of allergic diseases worldwide reflects some mangles of the existing pharmacotherapy concept which ignores some etiopathogenetic aspects of clinical atopy. Meanwhile, understanding cellular and molecular mechanisms of allergy may create prerequisites for development of new therapeutic areas, in order to effectively influence pathogenesis points of allergic inflammation and, thus, leading to therapeutic success. The review article concerns an antagonism between the two populations of T-helper cells (Th1 and Th2) carried out mainly by the action of IFNγ produced by activated Th1, and IL-4 secreted by activated Th2 which is at the heart of modern concept on the regulation of adaptive immunity. The prospects of immunotherapy of allergic diseases based on the polarization of the immune response are discussed, i.e., an activation of Th1 responses and Th2 suppression. This functional polarization can be mediated by the innate immune receptor agonist, i.e., synthetic and natural minimally-sized biologically active fragments (MBAF) with pathogen-associated molecular patterns. In this respect, a very promising drug registered in Russia is based on the synthetic MBAF, glucosaminylmuramyldipeptide (GMDP), The liсopid immunomodulator. This is due to the fact that GMDP, being an active substance of Liсopid, is a highly specific ligand for the NOD2 receptor of innate immunity factors; it may cause activation of the NF-kB transcription factor, and production of multiple immunoregulatory cytokines. Clinical and immunological efficacy of Licopid application in conventional therapy of atopic allergic diseases (asthma, atopic dermatitis, atopic variant of acute obstructive bronchitis) is presented as an overview of pre-clinical and clinical trials.N. V. KolesnikovaI. G. KozlovS. V. GuryanovaE. A. KokovT. M. AndronovaSPb RAACIarticleglucosaminyl muramyl dipeptide (gmdp)allergic diseasesatopypathogenesisigeImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 18, Iss 1, Pp 15-20 (2016)
institution	DOAJ
collection	DOAJ
language	RU
topic	glucosaminyl muramyl dipeptide (gmdp) allergic diseases atopy pathogenesis ige Immunologic diseases. Allergy RC581-607
spellingShingle	glucosaminyl muramyl dipeptide (gmdp) allergic diseases atopy pathogenesis ige Immunologic diseases. Allergy RC581-607 N. V. Kolesnikova I. G. Kozlov S. V. Guryanova E. A. Kokov T. M. Andronova CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES
description	Increased incidence of allergic diseases worldwide reflects some mangles of the existing pharmacotherapy concept which ignores some etiopathogenetic aspects of clinical atopy. Meanwhile, understanding cellular and molecular mechanisms of allergy may create prerequisites for development of new therapeutic areas, in order to effectively influence pathogenesis points of allergic inflammation and, thus, leading to therapeutic success. The review article concerns an antagonism between the two populations of T-helper cells (Th1 and Th2) carried out mainly by the action of IFNγ produced by activated Th1, and IL-4 secreted by activated Th2 which is at the heart of modern concept on the regulation of adaptive immunity. The prospects of immunotherapy of allergic diseases based on the polarization of the immune response are discussed, i.e., an activation of Th1 responses and Th2 suppression. This functional polarization can be mediated by the innate immune receptor agonist, i.e., synthetic and natural minimally-sized biologically active fragments (MBAF) with pathogen-associated molecular patterns. In this respect, a very promising drug registered in Russia is based on the synthetic MBAF, glucosaminylmuramyldipeptide (GMDP), The liсopid immunomodulator. This is due to the fact that GMDP, being an active substance of Liсopid, is a highly specific ligand for the NOD2 receptor of innate immunity factors; it may cause activation of the NF-kB transcription factor, and production of multiple immunoregulatory cytokines. Clinical and immunological efficacy of Licopid application in conventional therapy of atopic allergic diseases (asthma, atopic dermatitis, atopic variant of acute obstructive bronchitis) is presented as an overview of pre-clinical and clinical trials.
format	article
author	N. V. Kolesnikova I. G. Kozlov S. V. Guryanova E. A. Kokov T. M. Andronova
author_facet	N. V. Kolesnikova I. G. Kozlov S. V. Guryanova E. A. Kokov T. M. Andronova
author_sort	N. V. Kolesnikova
title	CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES
title_short	CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES
title_full	CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES
title_fullStr	CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES
title_full_unstemmed	CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES
title_sort	clinical and immunological efficiency of muramyl dipeptide in the treatment of atopic diseases
publisher	SPb RAACI
publishDate	2016
url	https://doaj.org/article/57fb33f05cbf4155ba78d2433241ed42
work_keys_str_mv	AT nvkolesnikova clinicalandimmunologicalefficiencyofmuramyldipeptideinthetreatmentofatopicdiseases AT igkozlov clinicalandimmunologicalefficiencyofmuramyldipeptideinthetreatmentofatopicdiseases AT svguryanova clinicalandimmunologicalefficiencyofmuramyldipeptideinthetreatmentofatopicdiseases AT eakokov clinicalandimmunologicalefficiencyofmuramyldipeptideinthetreatmentofatopicdiseases AT tmandronova clinicalandimmunologicalefficiencyofmuramyldipeptideinthetreatmentofatopicdiseases
_version_	1718422418133876736

CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF MURAMYL DIPEPTIDE IN THE TREATMENT OF ATOPIC DISEASES

Ejemplares similares